EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Herpes Zoster in Patients Treated with JAK Inhibitors for Immune-Mediated Inflammatory Diseases: Incidence, Associated Factors and Vaccination Uptake in a Real-World Cohort

António Parchão, Carolina Monteiro, Leonardo Araújo-Andrade, Cláudia Camila Dias iD, Cândida Abreu

Journal of Clinical Medicine · 13.05.2026 · 15 (10) · 3733

DOI: 10.3390/jcm15103733 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 13.05.2026. Verfasst von António Parchão und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Porto, Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: This study aimed to determine the incidence of herpes zoster (HZ) and risk factors associated with its occurrence in patients receiving Janus kinase inhibitors (JAKis) for immune-mediated inflammatory diseases (IMIDs), while evaluating preventive strategies and zoster vaccine uptake.

Methods

We conducted a retrospective single-center cohort study including patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, inflammatory bowel disease, atopic dermatitis and alopecia areata treated with upadacitinib, baricitinib or tofacitinib. The primary outcome was incident HZ during JAKi exposure. Incidence rates (IRs) were calculated per 100 person-years (PY) and Cox regression identified factors associated with HZ.

Results

A total of 292 patients contributed 565.5 PY of JAKi exposure. During follow-up, 23 patients (7.9%) developed HZ, corresponding to an overall IR of 4.07/100 PY (95% CI 2.40–5.73). Incidence rates were numerically lower with upadacitinib and varied across disease groups; differences were not statistically significant. Diabetes mellitus (HR 3.05, 95% CI 1.28–7.29) and chronic kidney disease (HR 3.24, 95% CI 1.17–8.95) were independently associated with HZ. Herpes simplex infection requiring systemic antiviral therapy was more frequent among patients who developed HZ. Recombinant zoster vaccine (RZV) uptake was low (9.9%), but higher among patients evaluated in a dedicated infectious risk consultation. No HZ events were observed among RZV-vaccinated patients. Although six HZ events (26.1%) were severe, all cases resolved completely.

Conclusions

HZ remains a relevant complication of JAKi therapy across IMIDs. Diabetes mellitus and chronic kidney disease may help identify higher-risk patients, while structured infectious risk assessment could improve vaccine uptake.

Schlagwörter

Stichwörter der Autor:innen

Janus kinase inhibitorsherpes zosterimmune-mediated inflammatory diseasesrecombinant zoster vaccine

Autor:innen und Institutionen

  • Faculty of Medicine, University of Porto, Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal.
  • Infectious Diseases Department, Unidade Local de Saúde São João, Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal.
  • NeuroGen Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Dr. Plácido da Costa, 4200-450 Porto, Portugal.
  • RISE-Health, Unit of Anatomy, Department of Biomedicine, Faculty of Medicine, University of Porto, Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal.
  • Knowledge Management Unit, Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal.
  • RISE-Health, Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine of the University of Porto, Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal.

ORCID-Profile: Cláudia Camila Dias

Zitieren

APA

Parchão, A., Monteiro, C., Araújo-Andrade, L., Dias, C. C., & Abreu, C. (2026). Herpes Zoster in Patients Treated with JAK Inhibitors for Immune-Mediated Inflammatory Diseases: Incidence, Associated Factors and Vaccination Uptake in a Real-World Cohort. Journal of Clinical Medicine, 15(10), 3733. https://doi.org/10.3390/jcm15103733

Vancouver

Parchão A, Monteiro C, Araújo-Andrade L, Dias CC, Abreu C. Herpes Zoster in Patients Treated with JAK Inhibitors for Immune-Mediated Inflammatory Diseases: Incidence, Associated Factors and Vaccination Uptake in a Real-World Cohort. Journal of Clinical Medicine. 2026;15(10):3733. doi:10.3390/jcm15103733

BibTeX
@article{Parcho2026,
  author = {Parchão, António and Monteiro, Carolina and Araújo-Andrade, Leonardo and Dias, Cláudia Camila and Abreu, Cândida},
  title = {Herpes Zoster in Patients Treated with JAK Inhibitors for Immune-Mediated Inflammatory Diseases: Incidence, Associated Factors and Vaccination Uptake in a Real-World Cohort},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {10},
  pages = {3733},
  doi = {10.3390/jcm15103733}
}
Kostenlos starten →